

## Vermillion, Inc. Announces the Launch of OVA1®+

### Description

#### **Vermillion, Inc. Announces the Launch of OVA1®+**

*The new best-in-class reflex offering combines strengths from OVA1® and OVERA®*

Access the full press release, [here](#).

**AUSTIN, Texas — October 9, 2018 — Vermillion, Inc. (NASDAQ: VRML)**, a bioanalytical-based women's health company focused on gynecologic disease, today announced the launch of its enhanced reflex offering OVA1®+, through its wholly owned subsidiary, ASPIRA Labs, Inc. The new best-in-class offering combines the strengths from both of its FDA-cleared proprietary technologies: OVA1® and OVERA® (MIA, MIA2G, Multivariate Index Assay 1<sup>st</sup> and 2<sup>nd</sup> generation), which evaluate ovarian cancer risk in women with a pelvic mass prior to surgical treatment. OVA1®+ is a reflex process which performs OVA1® and, if indicated due to elevated OVA1® results, also performs OVERA®.

"We are continuing to innovate on behalf of healthcare providers, patients and their families. Creating the OVA1®+ reflex process enhances the information already provided by OVA1® alone, and allows us to put even more information in the hands of clinicians," said [Valerie Palmieri](#), CEO of Vermillion. "The feedback from the initial pilot has been very positive, and we are excited to now be able to offer OVA1®+."

The OVA1®+ reflex process was created based on provider feedback. OVA1®+ allows customers to access the benefits of OVA1®, while providing the benefits of OVERA® when needed. When a reflex is indicated, the results for both OVA1® and OVERA® are reported on one clinical informatic report.

Combining these two proprietary tests as a reflex process leverages the strengths of each and provides enhanced information to healthcare providers.

Benefits of the OVA1®+ reflex process include:

- Maintaining the high early stage detection rate for risk of malignancy
- Improved intermediary risk test performance by 40%
- Continuing to provide up to a 98% negative predictive value, a low risk OVA1® result indicates a low malignancy risk

Currently, OVA1® is the only FDA cleared, American College of Obstetrics and Gynecologist (ACOG) endorsed, Medicare-covered, ovarian cancer risk assessment for all ages, all stages, all ethnicities and all cancer types. Plus, 40% of the lives in the US are under positive medical coverage for OVA1®.